Abstract
Purpose Differential tumor response to therapy is partially attributed to tumor heterogeneity. Additional efforts are needed to identify tumor heterogeneity parameters in response to therapy that are easily applicable in clinical practice. We aimed to describe tumor response-speed heterogeneity and evaluate its prognostic value in patients with metastatic colorectal cancer (mCRC).
Patients and Methods Individual patient data from Amgen (NCT00364013) and Sanofi (NCT00305188; NCT00272051) trials were retrieved from Project Data Sphere. Patients in the Amgen 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) arm were used to establish response-speed heterogeneity. Its prognostic value was subsequently validated in the Sanofi FOLFOX arms and the Amgen panitumumab + FOLFOX arm. Kaplan-Meier method and Cox proportional hazards models were used for survival analyses.
Results Patients with high response-speed heterogeneity in the Amgen FOLFOX cohort had significantly shorter (P<0.001) median progression-free survival (PFS) of 7.27 months (95%CI 6.12–7.96 months) and overall survival (OS) of 16.0 months (95%CI 13.8–18.2 months) than patients with low response-speed heterogeneity with median PFS of 9.41 months (95%CI 8.75– 10.89 months) and OS of 22.4 months (95%CI 20.1–26.7 months), respectively. Tumor response-speed heterogeneity was a poor prognostic factor of shorter PFS (HR 4.17, 95%CI 2.49–6.99, P<0.001) and shorter OS (HR 2.57, 95%CI 1.64–4.01, P<0.001), after adjustment for other common prognostic factors. Comparable findings were found in the external validation cohorts.
Conclusion Tumor response-speed heterogeneity to first-line chemotherapy was a novel prognostic factor associated with early disease progression and shorter survival in patients with mCRC.
Implications for Practice Routine clinical decision making heavily relies on radiographic assessment of disease response to therapy. For patients with heterogeneous tumors, the degree and kinetics of individual tumor response to the same therapy can sometimes be vastly different. We explored a novel quantitative parameter to describe response-speed heterogeneity by utilizing individual patient data from previous clinical trials. This parameter was an independent prognostic factor associated with early disease progression and shorter survival. Complementary to existing molecular and radiographic tumor heterogeneity parameters, it may help practicing oncologists describe tumor response disparity and serve as a new prognostic factor for patients with mCRC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
1. Approval was received to use the data in the present work or that the access to the data was granted after registration by Project Data Sphere https://data.projectdatasphere.org/projectdatasphere/html/home 2. Project Data Sphere Registration ID# to access the data of all three clinical trials is junjia.liu{at}einsteinmed.org 3. IRBs of each participating institutions in each clinical trial have given ethical approval for the collection of the original data in each clinical trial we referred to. Please refer to the following. 1. For https://data.projectdatasphere.org/projectdatasphere/html/content/309 refer to https://clinicaltrials.gov/ct2/show/study/NCT00364013 and https://www.nejm.org/doi/10.1056/NEJMoa1305275 2. For https://data.projectdatasphere.org/projectdatasphere/html/content/136 refer to Protocol in the above linked web page of Project Data Sphere and https://clinicaltrials.gov/ct2/show/NCT00305188 3. For https://data.projectdatasphere.org/projectdatasphere/html/content/137 refer to Protocol in the above linked web page of Project Data Sphere and https://clinicaltrials.gov/ct2/show/NCT00272051
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Research funding: None.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
